(Syndrome X, Insulin Resistance syndrome)

Slides:

Advertisements

Similar presentations

Section 1 Review. Pulmonary disease abnormal function obstructive sleep apnea hypoventilation syndrome Nonalcoholic fatty liver disease steatosissteatohepatitiscirrhosis.

Advertisements

1 Prediabetes Screening and Monitoring. 2 Prediabetes Epidemiologic evidence suggests that the complications of T2DM begin early in the progression from.

DO YOU HAVE THE METABOLIC SYNDROME? You're never too young to have it Jacqueline A. Eberstein, R.N.

Definitions Body Mass Index (BMI) describes relative weight for height: weight (kg)/height (m 2 ) Overweight = 25–29.9 BMI Obesity = >30 BMI.

CONTROLLING YOUR RISK FACTORS Taking the Steps to a Healthy Heart.

Metabolic Syndrome Symposium Dar Al-Kalima Health and Wellness Center Bethlehem, Palestine Oct

METABOLIC SYNDROME Dr. Kauser Usman (MD) Associate Professor Department of Medicine King George’s Medical University, Lucknow.

Cardio-Metabolic Syndrome Guidelines on Education, Detection and Early Treatment Heval Mohamed Kelli, PGY-2 Emory Internal Medicine Residency no conflict.

U.S. Dept of Health and Human Services. National High Blood Pressure Education Program. Seventh Report of Joint National Committee on Prevention, Detection,

Metabolic Syndrome Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference Circulation. 2004;109:

Lipids 101 Cardiology Board Review Med-Peds Style!

Linked Metabolic Abnormalities:

LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes (TLC) and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL)

Cardiovascular Disease in Women Module III: Risk Assessment Tool.

 #1 health concern in USA  38% of all deaths  1 in 2.7 Americans die from CVD  80 million Americans suffer from some form of CVD  Lower educational.

השמנת יתר חמד " ע פרופ ' ארדון רובינשטין.

Prediabetes Screening and Monitoring 1. Rationale for Prediabetes Screening Epidemiologic evidence suggests the complications of diabetes begin early.

Metabolic Syndrome. America’s Health Status one-third of U.S. adults (35.7%) are obese. 17% (12.5 million) of children 2—19 years are obese. Top leading.

Obesity M.A.Kubtan MD - FRCS M.A.Kubtan1. 2  Pulmonary Disease  Fatty Liver Disease  Orthopedic Disorders  Gallbladder Disease  Psychological Impact.

METABOLIC SYNDROME From PubMed Health A service of the National Library of Medicine, National Institutes of Health. A.D.A.M. Medical Encyclopedia, Atlanta,

METABOLIC Syndrome: a Global Perspective

Amber Leon Jeanine Mills Erin Prasad Nutrition Assessment and Therapy 1 Winter 2012.

Metabolic Syndrome Yusra Mir, MD Zunairah Syed, MD Harjagjit Maan, MD.

Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 1 of 4.

DYSLIPIDEMIAS: TYPES I-V Thomas F. Whayne, Jr, MD, PhD, FACC Professor of Medicine (Cardiology) University of Kentucky March 2011.

METABOLIC SYNDROME Prof. Mohamad S. Al-Hadramy Professor of Medicine/Consultant KAUH-Dept. of Medicine Prof. Mohamad S. Al-Hadramy Professor of Medicine/Consultant.

Organizational criteria for Metabolic Syndrome National Cholesterol Education Program Adult Treatment Panel III World Health OrganizationAmerican Association.

KSU Biochemistry department sciences college Dr.Howaida Nounou Bnazeer AL-Mutiri Eman AL-Musa Ahood AL-Onazy Sua’ad AL-Otibie Amjad AL-Otibie.

GDM-DEFINITION Gestational Diabetes Mellitus (GDM) is defined as ‘carbohydrate intolerance with recognition or onset during pregnancy’, irrespective of.

Diabetes National Diabetes Control Programme

METABOLIC SYNDROME From PubMed Health A service of the National Library of Medicine, National Institutes of Health. A.D.A.M. Medical Encyclopedia, Atlanta,

The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.

The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Part 3 Stan Schwartz MD, FACP, FACE.

Plasminogen-Activating Inhibitor-1 (PAI-1) High PAI-1 associated with: Obesity (especially visceral), possible fatty liver. 2,3,4 Inflammation and oxidative.

Dr. I. Selvaraj Indian Railways Medical Service B.Sc., M.B.B.S., M.D.,D.P.H., D.I.H., PGCHFW ( NIHFW,New Delhi)., Life member of Indian Association of.

Insulin Resistance Progression to Diabetes. Hypertension: BP >140/90 Dyslipidemia: ◦TG >150 mg/dL (1.7 mmol.L) ◦HDL-C

Metabolic Syndrome Darwin Deen, MD, MS Albert Einstein College of Medicine Gina Lopez, MSII Sophie Davis School of Biomedical Education.

Paul Zimmet & George Alberti

Chapter 14 Patterns in Health and Disease: Epidemiology and Physiology EXERCISE PHYSIOLOGY Theory and Application to Fitness and Performance, 6th edition.

Risk Factors: Measure and Modify Nina Radford MD Cardiovascular Medicine Department Director, Clinic Research Cooper Clinic, Dallas Texas.

Diabetes. Objectives: Diabetes Mellitus (DM) Discuss the prevalence of diabetes in the U.S. Contrast the main types of diabetes. Describe the classic.

Metabolic Syndrome Endocrine Block 1 Lecture Dr. Usman Ghani.

PREVALENCE AND RISK FACTORS FOR NON- ALCOHOLIC FATTY LIVER DISEASE AMONG AN URBAN AGING ADULT SRI LANKAN POPULATION– RAGAMA HEALTH STUDY 7-YEAR FOLLOW.

Chapter Metabolic Syndrome Peterson and Gordon C H A P T E R.

Yusra Mir, MD Zunairah Syed, MD Harjagjit Maan, MD

Metabolic syndrome: Evidences from the Korean National Health and Nutrition Examination Survey Tran Binh Thang, MPH National Cancer Center Graduate School.

Role of mediterranean diet in combating the problem of Syndrome x

Endocrine Block 1 Lecture Dr. Usman Ghani

Endocrine Block Dr. Usman Ghani

Menopause and Metabolic Syndrome

Baseline characteristics and effectiveness results

By Dr. Sumbul Fatma Clinical Chemistry Unit Department of Pathology

Treatment of Type 2 Diabetes: Pathophysiology Conclude: do so without Hypoglycemia or Visceral Fat Weight Gain 1.

Endocrine Block 1 Lecture Dr. Usman Ghani

CHILDHOOD OBESITY “An emerging challenge”

ASSOCIATIONS OF METABOLIC SYNDROME COMPONENTS WITH CRITERIA FOR THE CLINICAL DIAGNOSIS OF THE METABOLIC SYNDROME AS PROPOSED BY THE NCEP-ATP III Metabolic.

Effect of Metabolic Surgery on diabetes and hypertension

Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Risks and Assessment NHLBI Obesity Education.

Heart Health & Diabetes

Screening and Monitoring

برنامه غربالگری و بیماریابی بیماری های قلبی عروقی و عوامل خطر آن در استان فارس معاونت بهداشتی دانشگاه علوم پزشکی شیراز واحد غیر واگیر برنامه قلب و عروق.

Screening and Monitoring

Macrovascular Complications Microvascular Complications

Metabolic Syndrome Warren Heffron MD Professor EmeritusFamily Medicine

Metabolic Syndrome (N=160) Non-Metabolic Syndrome (N=138) 107/53

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Level of risk factor control in the overall sample and by gender

Insert Case Title Case Overview

Prepared by :Dr. Latifa Mari’e

Presentation transcript:

(Syndrome X, Insulin Resistance syndrome) Metabolic Syndrome (Syndrome X, Insulin Resistance syndrome) www.ppttopics.com

25% of pop, nonobese, nondiabetic => Hyperglycemia (not nessisary DM) => Triacylglycerides + low HDL => BP => Syndrome X www.ppttopics.com

Epidemiology USA: 44% in pop >50y (60%w, 45%m) France: 30-64 y <10%, >65y 17,5% Increasing risk with age www.ppttopics.com

Diagnostic criteria NCEP:ATPIII criteria 3 or more: Waist circumference >102cm (M),>88cm (W) Hypertriglyceridemia: >or= 150mg/dl HDL <40mg/dl (M), <50 (W) Hypertension: >130/85 Fasting plasma glucose >100mg/dl (or diagnosed DM 2) www.ppttopics.com

Pathophysiology Insulin resistance Hyperlipidemia www.ppttopics.com

Symptoms www.ppttopics.com

Symptoms only associated with other diseases. www.ppttopics.com

Features + LDL Hyperuricidemia Abd obesity Prothrombotic state Plasminogen activator inhibitor type 1 (PAI-1) Proinflammatory state www.ppttopics.com

Associated diseases Cardiovascular inc stroke and MI Type 2 diabetes Non alcoholic fatty liver disease Polysystic ovary syndrome Obstructive sleep apnea www.ppttopics.com

Treatment LIFESTYLE DIET PHYSICAL ACTIVITY www.ppttopics.com

Medication Appetitesuppresants: Phentermine Absorption inhibitors:Orlistat Statins: LDL+ triacylglycerides+ HDL Fibrates/Nicotinic acid: Triacyl glycerides Antihypertensives Metformin: Glucose Thiazolidinediones: Glucose www.ppttopics.com